NASDAQ:BNTX - BioNTech Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $106.50
  • Forecasted Upside: -29.72 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$151.54
▲ +10.82 (7.69%)
1 month | 3 months | 12 months
Get New BioNTech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BNTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BNTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$106.50
▼ -29.72% Downside Potential
This price target is based on 7 analysts offering 12 month price targets for BioNTech in the last 3 months. The average price target is $106.50, with a high forecast of $130.00 and a low forecast of $62.00. The average price target represents a -29.72% upside from the last price of $151.54.
Hold
The current consensus among 7 investment analysts is to hold stock in BioNTech.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
4/22/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
7/21/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
10/19/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/17/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2021SVB LeerinkBoost Price TargetMarket Perform$110.00 ➝ $118.00High
i
4/6/2021SVB LeerinkBoost Price TargetMarket Perform$106.00 ➝ $110.00Low
i
4/6/2021Berenberg BankSet Price TargetBuy$130.00Medium
i
4/6/2021JPMorgan Chase & Co.Set Price TargetNeutral$104.00Medium
i
3/31/2021JPMorgan Chase & Co.Reiterated RatingNeutral$104.00Low
i
3/31/2021Berenberg BankReiterated RatingBuy$130.00Medium
i
2/4/2021SVB LeerinkBoost Price TargetMarket Perform$97.00 ➝ $106.00Low
i
1/11/2021Berenberg BankSet Price TargetBuy$126.00High
i
12/15/2020SVB LeerinkBoost Price TargetMarket Perform$91.00 ➝ $97.00Low
i
12/14/2020Canaccord GenuityBoost Price TargetBuy$115.00 ➝ $130.00High
i
11/30/2020Bank of AmericaDowngradeBuy ➝ Neutral$123.00 ➝ $126.00High
i
Rating by Tazeen Ahmad at Bank of America Co.
11/24/2020SVB LeerinkBoost Price TargetMarket Perform$90.00 ➝ $91.00Low
i
11/16/2020Berenberg BankReiterated RatingBuy$126.00Medium
i
11/10/2020JPMorgan Chase & Co.Set Price TargetNeutral$90.00Medium
i
11/10/2020SVB LeerinkBoost Price TargetMarket Perform$64.00 ➝ $90.00High
i
11/9/2020Canaccord GenuityBoost Price TargetBuy$97.00 ➝ $112.00High
i
10/29/2020CommerzbankInitiated CoverageBuy$119.00High
i
10/14/2020SVB LeerinkBoost Price TargetPositive ➝ Market Perform$62.00 ➝ $69.00High
i
9/22/2020Berenberg BankReiterated RatingBuy$98.00Medium
i
8/6/2020SVB LeerinkBoost Price TargetMarket Perform$42.00 ➝ $69.00High
i
8/3/2020Berenberg BankInitiated CoverageBuy$98.00Medium
i
7/27/2020HC WainwrightReiterated RatingHoldLow
i
Rating by Robert Burns at HC Wainwright
7/21/2020Canaccord GenuityBoost Price TargetPositive ➝ Buy$75.00 ➝ $97.00Low
i
7/21/2020Bank of AmericaUpgradeNeutral ➝ Buy$71.00 ➝ $105.00Low
i
7/20/2020Bank of AmericaUpgradeNeutral ➝ Buy$71.00 ➝ $105.00Low
i
7/14/2020HC WainwrightReiterated RatingHoldHigh
i
Rating by R. Burns at HC Wainwright
7/13/2020Canaccord GenuityBoost Price TargetBuy$60.00 ➝ $75.00Low
i
7/2/2020Bryan, Garnier & CoBoost Price Target$50.00 ➝ $62.00High
i
7/2/2020SVB LeerinkBoost Price TargetPositive ➝ Market Perform$37.00 ➝ $42.00High
i
Rating by D. Graybosch at SVB Leerink LLC
6/30/2020HC WainwrightDowngradeBuy ➝ NeutralMedium
i
Rating by R. Burns at HC Wainwright
6/25/2020HC WainwrightLower Price TargetBuy$69.00 ➝ $63.00High
i
Rating by R. Burns at HC Wainwright
5/19/2020HC WainwrightUpgradeNeutral ➝ Buy$48.00 ➝ $69.00High
i
Rating by R. Burns at HC Wainwright
4/28/2020Bank of AmericaDowngradeBuy ➝ Neutral$51.00Medium
i
4/13/2020HC WainwrightReiterated RatingNeutral$30.00 ➝ $48.00High
i
Rating by R. Burns at HC Wainwright
4/3/2020Canaccord GenuityBoost Price TargetBuy$22.00 ➝ $60.00High
i
3/18/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$23.00 ➝ $33.00High
i
3/17/2020HC WainwrightReiterated RatingHold$30.00High
i
Rating by R. Burns at HC Wainwright
3/9/2020HC WainwrightInitiated CoverageNeutral$30.00High
i
Rating by R. Burns at HC Wainwright
1/22/2020UBS GroupDowngradeBuy ➝ Neutral$21.00 ➝ $35.00Medium
i
11/5/2019Wolfe ResearchInitiated CoverageOutperform$21.00 ➝ $21.00Low
i
11/4/2019SVB LeerinkInitiated CoverageOutperformHigh
i
11/4/2019Berenberg BankInitiated CoverageBuy$25.00High
i
11/4/2019Bank of AmericaInitiated CoverageBuy ➝ Buy$21.00 ➝ $21.00High
i
11/4/2019Canaccord GenuityInitiated CoverageBuy$22.00High
i
11/4/2019JPMorgan Chase & Co.Initiated CoverageOverweight$23.00High
i
11/4/2019UBS GroupInitiated CoverageBuy$21.00High
i
(Data available from 4/17/2016 forward)
BioNTech logo
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Read More

Today's Range

Now: $151.54
$141.49
$152.32

50 Day Range

MA: $107.63
$90.29
$140.72

52 Week Range

Now: $151.54
$37.00
$140.79

Volume

4,624,324 shs

Average Volume

1,999,994 shs

Market Capitalization

$36.60 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of BioNTech?

The following Wall Street sell-side analysts have issued reports on BioNTech in the last year: Bank of America Co., Berenberg Bank, Bryan, Garnier & Co, Canaccord Genuity, Commerzbank AG, HC Wainwright, JPMorgan Chase & Co., SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for BNTX.

What is the current price target for BioNTech?

8 Wall Street analysts have set twelve-month price targets for BioNTech in the last year. Their average twelve-month price target is $106.50, suggesting a possible downside of 29.7%. Canaccord Genuity has the highest price target set, predicting BNTX will reach $130.00 in the next twelve months. Bryan, Garnier & Co has the lowest price target set, forecasting a price of $62.00 for BioNTech in the next year.
View the latest price targets for BNTX.

What is the current consensus analyst rating for BioNTech?

BioNTech currently has 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BNTX, but not buy more shares or sell existing shares.
View the latest ratings for BNTX.

What other companies compete with BioNTech?

How do I contact BioNTech's investor relations team?

BioNTech's physical mailing address is AN DER GOLDGRUBE 12, MAINZ 2M, 55131. The company's listed phone number is 49-61-31908-40 and its investor relations email address is [email protected] The official website for BioNTech is www.biontech.de.